New Requests for Information posted: ENACT and Solving Sepsis

RFI Banner

BARDA Announces Requests for Information: Solving Sepsis and ENACT

BARDA has issued two new Requests for Information (RFI) for transformative tools and technologies to disrupt the current treatment paradigm on Sepsis and for early detection and diagnosis of chemical and biological exposures and infections.

Overcoming major challenges in the national health security ecosystem requires breakthrough solutions. The Assistant Secretary for Preparedness and Response (ASPR) within the Department of Health and Human Services has charged the Biomedical Advanced Research and Development Authority (BARDA) to rapidly accelerate the identification, development and delivery of novel solutions to all citizens for priority areas of concern.

BARDA is soliciting relevant information on the current and planned capabilities and intent of industry and academic investigators to address some of the hardest challenges faced today.

New BARDA Funding Opportunity Announcement: BARDA Division of Research, Innovation and Ventures (DRIVe) Accelerator Network

About the DRIVe Accelerator Network:

BARDA’s Division of Research, Innovation and Ventures (DRIVe), will stimulate public-private partnership collaborations that spur innovation and investment in health security products and technologies. This Funding Opportunity Announcement is for a DRIVe Accelerator Network, where accelerators work together to identify promising, innovation and then provide wraparound technical and business development support services to programs funded by DRIVe.

DRIVe Accelerator Network support teams will bring together a network of multiple accelerators, to leverage their individual strengths toward product developers funded by DRIVe. Product development candidates that graduate from DRIVe with support of the DRIVe Accelerator Network will be better positioned for advanced R&D investment, clinical development, and commercialization.

Please respond by May 17, 2018.


About Solving Sepsis:

Solving Sepsis Logo

Sepsis is among the top leading causes of death in US hospitals (~35%) and among the top most expensive conditions treated in US hospitals, representing approximately 6% of all hospitalizations, as well as a leading cause of hospital readmission. More than 1.7 million people in the US are diagnosed with sepsis with more than 250,000 dying each year. Despite many advances effective treatment strategies for sepsis have remained elusive.

Solving Sepsis seeks relevant information on the current and planned capabilities and intent of industrial and academic investigators to address sepsis. Various information, data, videos and materials may be submitted to support interest and capability to develop novel approaches to the diagnosis, management and treatment of sepsis. Of particular interest are existing or planned databases for sepsis clinical data; enabling rapid and reliable early indicators of sepsis and its severity; and, techniques and devices that improve outcomes by modifying disease management; and therapeutic agents that positively impact survival and substantively reduce post-sepsis morbidity.

Please respond by May 7, 2018.



The goal of ENACT is to solve the problem of late identification of exposures or infections and cascading signals to illness and death. BARDA is interested in exploring the potential for developing and demonstrating the capability to develop transformational technologies that can be deployed either on person or near-person to identify changes to normal health function of individuals (e.g. individuals who are already exposed to chemical and biological threats and are pre-symptomatic). ENACT seeks information on technologies to identify, characterize, and broadly adapt biological, biometric, behavioral and physiological signatures that can determine health status among pre-infected pre-symptomatic and post-infected pre-symptomatic disease stages, and predict health outcomes from recovery to homeostasis or progression to severe illness and death.

Please respond by May 7, 2018.